Cronos Group, Inc. (CRON) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

97.76 k

Shareholding (Mar 2025)

FII

13.92%

Held by 321 FIIs

DII

85.59%

Held by 7 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Positive results for the last 7 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CAD 27.45 MM
OPERATING PROFIT MARGIN(Q) Highest at -1.06 %
RAW MATERIAL COST(Y) Fallen by -120.64% (YoY)

With ROE of 1.42%, it has a attractive valuation with a 0.92 Price to Book Value

Increasing Participation by Institutional Investors

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 1,353 Million (Small Cap)

P/E

66.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.77

Return on Equity

1.42%

Price to Book

0.92

Revenue and Profits:

Net Sales:

46 Million

(Quarterly Results - Jun 2025)

Net Profit:

-53 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

25.99%

6 Months

23.32%

1 Year

0.87%

2 Years

55.8%

3 Years

0.58%

4 Years

-67.08%

5 Years

-65.68%

Cronos Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

30.84%

EBIT Growth (5y)

12.06%

EBIT to Interest (avg)

-152.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.78

Sales to Capital Employed (avg)

0.09

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

17.06%

ROCE (avg)

ROE (avg)

1.03%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.94

EV to EBIT

-4.67

EV to EBITDA

-7.10

EV to Capital Employed

0.74

EV to Sales

1.38

PEG Ratio

0.06

Dividend Yield

ROCE (Latest)

-15.78%

ROE (Latest)

1.42%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 7 Schemes (0.5%)

Foreign Institutions

Held by 321 Foreign Institutions (13.92%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 9.20% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -580.18% vs -81.92% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.30",
          "val2": "46.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.50",
          "val2": "-1.00",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "-0.70",
          "chgp": "-171.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-53.30",
          "val2": "11.10",
          "chgp": "-580.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-136.20%",
          "val2": "-109.00%",
          "chgp": "-2.72%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.87% vs 4.25% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 157.62% vs 52.92% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "161.10",
          "val2": "117.70",
          "chgp": "36.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-67.40",
          "val2": "-97.20",
          "chgp": "30.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.70",
          "val2": "-54.50",
          "chgp": "85.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "54.80",
          "val2": "-95.10",
          "chgp": "157.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-497.50%",
          "val2": "-916.00%",
          "chgp": "41.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

46.30

Operating Profit (PBDIT) excl Other Income

-0.50

-1.00

50.00%

Interest

0.00

Exceptional Items

-1.90

-0.70

-171.43%

Consolidate Net Profit

-53.30

11.10

-580.18%

Operating Profit Margin (Excl OI)

-136.20%

-109.00%

-2.72%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 9.20% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -580.18% vs -81.92% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

161.10

117.70

36.87%

Operating Profit (PBDIT) excl Other Income

-67.40

-97.20

30.66%

Interest

0.00

Exceptional Items

-7.70

-54.50

85.87%

Consolidate Net Profit

54.80

-95.10

157.62%

Operating Profit Margin (Excl OI)

-497.50%

-916.00%

41.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 36.87% vs 4.25% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 157.62% vs 52.92% in Dec 2023

All Annual Results

Company CV

About Cronos Group, Inc.

Cronos Group, Inc.

Pharmaceuticals & Biotechnology

Cronos Group Inc is a cannabinoid company. The Company is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and Rest of World. The United States segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. The Company’s subsidiaries include Cronos Israel G.S. Cultivations Ltd, Cronos Israel G.S. Manufacturing Ltd, Cronos Israel G.S. Store Ltd and Cronos Israel G.S. Pharmacies Ltd.

Company Coordinates

Company Details

Suite 300, 111 Peter Street , TORONTO ON : M5V 2G9

Tel: 1 416 5040004

https://thecronosgroup.com/

Registrar Details